Top Net Payout Yield Companies To Buy Right Now

Our warming planet poses an increasing risk to business operations, and some companies are managing better than others. For instance, NRG Energy (NYSE: NRG  ) and some other utilities are rethinking the entire electrical grid in the wake of repeated storm destruction. Wal-Mart (NYSE: WMT  ) is pursuing new efficiency mechanisms to make its supply chain more resilient to shocks.

John Vechey of PopCap Games recently joined The Motley Fool for a climate change summit. His first panel guests were Dr. Rachel Cleetus and Dr. Joe Casola. Dr. Cleetus is a climate economist with the Union of Concerned Scientists, and Dr. Casola is program director for science and impacts at the Center for Climate and Energy Solutions. They both offer insights in this video into what investors should look for when considering how a particular company is coping with climate change and responding to risk in today's changing world.

In light of climate change pressures, the energy sector may change dramatically in the coming years. One home-run investing opportunity in this space has been slipping under Wall Street's radar for months. But it won't stay hidden much longer. Forward-thinking energy players like GE and Ford have already plowed sizable amounts of research capital into this little-known stock... because they know it holds the key to the explosive profit power of the coming "no choice fuel revolution." Luckily, there's still time for you to get on board if you act quickly. All the details are inside an exclusive report from The Motley Fool. Click here for the full story!

Hot Gas Companies To Invest In Right Now: Kindred Healthcare Inc. (KND)

Kindred Healthcare, Inc. operates as a healthcare services company in the United States. The company�s Hospital division operates long-term acute care (LTAC) and inpatient rehabilitation (IRFs) hospitals, which provide services to medically complex patients, including the critically ill, suffering from multiple organ system failures, primarily the cardiovascular, pulmonary, kidney, gastro-intestinal, and skin systems, as well as life-threatening infections. Its Nursing Center division operates nursing and rehabilitation centers, and assisted living facilities that offer short stay patients and long stay residents with a range of medical, nursing, rehabilitative, pharmacy, and routine services. It also provides specialized programs for residents suffering from Alzheimer�s disease and other dementias through its reflections units. The company�s Rehabilitation division provides rehabilitation services, including physical and occupational therapies, and speech pathology ser vices under the RehabCare name to residents and patients of nursing centers, LTAC hospitals, outpatient clinics, home health agencies, assisted living facilities, school districts, and hospice providers. In addition, it offers specialized care programs that address medical needs, such as wound care, pain management, and cognitive retraining; and programs for neurologic, orthopedic, cardiac, and pulmonary conditions. Its Home Health and Hospice division offers home health, hospice, and private duty services to patients in various settings comprising homes, skilled nursing facilities, and other residential settings. As of December 31, 2011, it operated 121 LTAC hospitals with 8,597 licensed beds, and 5 IRFs with 183 licensed beds in 26 states; and 224 nursing and rehabilitation centers with 27,148 licensed beds, and 6 assisted living facilities with 413 licensed beds in 27 states. The company was founded in 1998 and is headquartered in Louisville, Kentucky.

Advisors' Opinion:

• [By Erin McCarthy]

  Gentiva Health Services Inc.(GTIV) confirmed Thursday that its board has rejected Kindred Healthcare Inc.'s(KND) $533 million takeover bid, saying the proposal significantly undervalues the company.

• [By Anna Prior]

  Kindred Healthcare Inc.(KND) boosted its offer to about $589 million to buy a smaller stake in Gentiva Health Services Inc.(GTIV), as it tries to draw the home health-care company to the negotiating table.

• [By Brad Thomas]

  As the only healthcare REIT with a "hospital-focused" platform, MPW is a relatively new REIT that was formed (in 2004) to lease from many of the nation's leading hospital operators, including Prime Healthcare Services, Kindred Healthcare (KND), HealthSouth (HLS), Health Management Associates (HMA), Community Health Systems (CYH), Vibra Healthcare, Ernest Health Inc., and IASIS Healthcare.

Top Net Payout Yield Companies To Buy Right Now: Buhler Industries Inc (BIIAF.PK)

Buhler Industries Inc. is a manufacturer of a range of agricultural equipment marketed throughout North America under three primary brand names Versatile, Allied, and Farm King. The Company�� principal products are tractors, self-propelled and pull-type sprayers, frontend loaders, grain augers, snow blowers, tillers, finishing mowers, feed processing equipment, seeding and tillage equipment and hay and forage equipment. The Company�� factories include the Winnipeg (Clarence) factory, the Morden, Manitoba factory, the Winnipeg (Regent) factory, the Bradley Steel Processors��factory, the Fargo factory, the Salem factory, the Willmar factory and the Vegreville factory. The Company�� subsidiaries include John Buhler Inc., Progressive Manufacturing Ltd., Amarillo Service & Supply Inc., Haskett Properties Inc., Buhler Versatile Inc, Haskett Investments Ltd., Buhler Finance Inc. and Buhler Ezee-On, Inc. Advisors' Opinion:

• [By Seth Barkett]

  Buhler Industries Inc. (BIIAF.PK) is headquartered in Winnipeg, Manitoba, Canada. The company was established in 1932 as an agricultural equipment manufacturer. It was purchased by John Buhler in 1969 and in 2007, Combine Factory Rostselmash Ltd. acquired 80% of the company's stock. Through steady expansion, new products and distribution channels, and acquisitions, Buhler has experienced impressive growth. With seven manufacturing plants across Canada and the United States as well as a great collection of brands like Farm King, Allied, Inland, and Versatile, this vertically-integrated manufacturer is an excellent way to invest in the global agricultural boom.

Top Net Payout Yield Companies To Buy Right Now: Conmed Corp (CNMD)

CONMED Corporation (CONMED), incorporated on February 10, 1970, is a medical technology company/ The Company emphasizes on surgical devices and equipment for minimally invasive procedures and monitoring. The Company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The Company operates in five segments: CONMED Endoscopic Technologies, CONMED Endosurgery, CONMED Electrosurgery, CONMED Linvatec and CONMED Patient Care.

Arthroscopy

The Company offers a range of devices and products for uses in arthroscopic surgery. The Company's arthroscopy products include powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, metal and bioabsorbable implants as well as related disposable products and fluid management systems. The Company also offers a line of video Endoscopy products suitable for uses in multi-specialty clinical environments beyond orthopedic arthroscopy, including laparoscopy, ear, nose and throat (ENT), gynecology and urology, as well as integrated operating room systems and equipment.

Powered Surgical Instruments

Electric, battery or pneumatic powered surgical instruments are used to perform orthopedic, arthroscopic and other surgical procedures where cutting, drilling or reaming of bone is required. Each power system consists of one or more handpieces and related accessories as well as disposable and limited reusable items (e.g., burs, saw blades, drills and reamers). Powered instruments are categorized as either small bone, large bone or specialty powered instruments. Specialty powered instruments are utilized in procedures such as spinal surgery, neurosurgery, ENT, oral/maxillofacial surgery, and cardiothoracic surgery.

The Company's line of powered instruments is sold principally under the Hall Surgical brand name, for use in large and small bone orthopedic, arthroscopic, oral/maxillofaci! al, podiatric, plastic, ENT, neurological, spinal and cardiothoracic surgeries. Large bone, neurosurgical, spinal and cardiothoracic powered instruments are sold primarily to hospitals while small bone arthroscopic, otolaryngological and oral/maxillofacial powered instruments are sold to hospitals, outpatient facilities and physicians offices.

The Company's powered instruments product line includes the MPower battery system. This orthopedic power system is specifically designed to meet the requirements of orthopedic applications. The MPower battery system allows a facility to purchase a single power system to perform total joint arthroplasty, trauma, arthroscopy, and small bone procedures. The system also provides a multitude of battery technologies to meet the varying needs of hospitals worldwide.

Electrosurgery

The use of electrosurgical units and associated surgical tools is commonplace in the hospital surgical suite, surgery centers, clinics and physician offices. Electrosurgery is routinely used to cut and coagulate tissue and small vessels in open and laparoscopic procedures using energy produced through radio frequency (RF) technology. Electrosurgery can be used in almost all surgical procedures including specialties, such as general, gynecology, orthopedics, cardiology, thoracics, urology, neurology, and dermatology. The Company�� portfolio consist of energy-based products is the Argon Beam Coagulation (ABC) technology. ABC technology combines the use of argon gas and electrosurgical energy to allow the surgeon to produce a surface coagulation which results in less tissue damage.

Patient Care

The Company's patient care product line includes a line of vital signs and cardiac monitoring products, including pulse oximetry equipment and sensors, electrocardiogram (ECG) electrodes and cables, cardiac defibrillation and pacing pads and blood pressure cuffs. The Company also offers a line of suction instruments and tubing for use in the! operatin! g room, as well as a line of intravenous (IV) products for use in the critical care areas of the hospital.

Endosurgery

Endosurgery (also referred to as minimally invasive surgery or laparoscopic surgery) is surgery performed without a incision. The Company's Endosurgical products include the Reflex and PermaClip clip appliers for vessel and duct ligation, Universal S/I (suction/irrigation) and Universal Plus laparoscopic instruments and specialized suction/irrigation electrosurgical instrument systems for use in laparoscopic surgery. The Company also offers cutting and dilating trocars, suction/irrigation accessories, laparoscopic scissors, dissectors and graspers, active electrodes, insufflation needles and linear cutters and staplers for use in laparoscopic surgery. The Company's disposable skin staplers are used to close large skin incisions with surgical staples, thus eliminating the time consuming suturing process. CONMED Endosurgery also offers a uterine manipulator called VCARE for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures.

Endoscopic Technologies

The Company offers a line of minimally invasive diagnostic and therapeutic products used in conjunction with procedures, which requires flexible endoscopy. The Company's principal customers include gastrointestinal (GI) endoscopists, pulmonologists, and nurses who perform both diagnostic and therapeutic endoscopic procedures in hospitals and outpatient clinics.

The Company's primary focus is to identify, develop, acquire, manufacture and market differentiated medical devices, which improve outcomes in the diagnosis and treatment of gastrointestinal and pulmonary disorders. The Company's diagnostic and therapeutic product offerings for GI and pulmonology include mucosal management devices, forceps, scope management accessories, bronchoscopy devices, dilatation, stricture management devices, hemostasis, biliary devices, and ! polypecto! my.

The Company competes with Smith & Nephew, plc, Arthrex, Inc., Stryker Corporation, ArthroCare Corporation, Johnson & Johnson: DePuy Mitek, Inc., Biomet, Inc., Medtronic, Inc. Midas Rex and Xomed, Synvasive Technology, Inc., Synthes, Inc., MicroAire Surgical Instruments, LLC, Zimmer Holdings, Inc., Covidien Ltd.; Valleylab, Medline Industries, Inc., ERBE Elektromedizin GmbH, Megadyne, Kendall, 3M Company, Ethicon Endo-Surgery, Inc, U.S.Surgical, Boston Scientific Corporation, Wilson-Cook Medical, Inc, Olympus America, Inc. and STERIS Corporation.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on CONMED (Nasdaq: CNMD  ) , whose recent revenue and earnings are plotted below.

• [By Seth Jayson]

  Margins matter. The more CONMED (Nasdaq: CNMD  ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong CONMED's competitive position could be.

• [By James Brumley]

  Shares of MDT stock have fallen 6% since their early January peak, but have been in an uptrend since late 2011 … one of the few stocks in the medical device world that has been rock-solid in a rocky environment.

  Medical Devices: ConMed Corp. (CNMD)

  With a market cap of only $1.2 billion, ConMed Corp. (CNMD) isn’t exactly a household name. That doesn’t mean CNMD stock can’t be a potent addiction to a portfolio, though.

• [By ovenerio]

  In the medical devices business (83% of FY 13 sales), the company competes with good health care companies such as Johnson & Johnson (JNJ), C.R. Bard (BCR) and ConMed (CNMD).

Top Net Payout Yield Companies To Buy Right Now: Evolva Holding SA (EVE)

Evolva Holding SA (Evolva) discovers and provides ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create small molecule compounds and their production routes. The Company�� nutrition and consumer products include Pomecins, saffron, stevia, vanilla and resveratrol. The Company�� pharmaceuticals products include EV-077 and EV-035. In pharmaceuticals, the Company focuses on oral, small molecule drugs with application in complications of diabetes and infectious diseases. Pomecins are Evolva�� compounds. Evolva is focused on two members of the family - Pomecin A and Pomecin B. EV-035 is a bacterial type II topoisomerase inhibitor. Evolva is developing EV-077 for the treatment of diabetic complications. It is an oral, small molecule compound, belonging to a structural class. Advisors' Opinion:

• [By Glenwoods]

  Earlier this year the giant food processor, Cargill, partnered with the small Swiss company, Evolva (SIX:EVE), which was developing its own stevia-based fermentation process, also in the pilot stage. As noted earlier in the article, Cargill is in a partnership with Coca-Cola for Truvia, the bestselling stevia product on the market. The success of the Cargill/Evolva partnership could have big implications not just for Cargill and Coca-Cola, but also on the entire stevia and sweetener market. I further believe the success of the partnership could have a major impact on Stevia First. If Cargill�� fermentation method produces a better tasting stevia product at a lower cost it would give Coca-Cola a considerable advantage over the other beverage bottlers, food manufacturers, and stevia producers. Such an outcome would force these companies to scramble to find a similar method in order to compete. There would be a very good chance that rival companies, in order to stay in the game, would have to turn to the other company developing a fermentation-based stevia product-- Stevia First. If that happens Stevia First�� value would rise considerably.

Top Net Payout Yield Companies To Buy Right Now: Tetraphase Pharmaceuticals Inc (TTPH)

Tetraphase Pharmaceuticals, Inc., incorporated on July 7, 2006, is a clinical stage biopharmaceutical company. The Company�� product candidate, eravacycline, is a fully synthetic tetracycline derivative that the Company are developing as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections. The Company�� frequently used products, such as Zyvox and Cubicin, are limited to Gram-positive bacteria and thus are rarely used as a first-line empiric monotherapy if broad bacterial coverage is required. During the year ended December 31, 2012, completed a Phase 2 clinical trial of eravacycline with intravenous administration for the treatment of patients with complicated intra-abdominal infections, or cIAI, and are finalizing its pivotal Phase 3 program for eravacycline. In 2012, in vitro experiments, eravacycline has demonstrated the ability to cover a variety of multi-drug resistant Gram-negative, Gram-positive, anaerobic and atypical bacteria, including multi-drug resistant Klebsiella pneumoniae, the species of Gram-negative bacteria that killed seven patients at the Clinical Center of the National Institutes of Health.

Gram-positive bacteria that have developed resistance to existing drugs include: Streptococcus pneumoniae that cause pneumonia, ear infections, bloodstream infections and meningitis; Staphylococcus aureus that cause skin, bone, lung and bloodstream infections, and Enterococci that are responsible for infections transmitted in healthcare settings. Gram-negative bacteria that have developed resistance to existing drugs include: Escherichia coli that cause urinary tract, skin and bloodstream infections; Salmonella and Escherichia coli that cause foodborne infections, and Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella spp.

In addition, other antibiotics that have been used as first-line empiric monothe! rapies, such as Levaquin, piperacillin/tazobactam, which is marketed by Pfizer as Zosyn, carbapenems, such as Merrem, and imipenem/cilastatin, which is marketed by Merck as Primaxin, have seen their utility as first-line empiric monotherapies diminished as the number of bacterial strains resistant to these therapies has increased. In addition to developing an intravenous formulation of eravacycline, the Company is also developing an oral formulation. A number of previous tetracyclines have been available in both intravenous and oral dosage forms. Infections that are resistant to existing oral drugs are increasingly common, and the Company believe that an intravenous-to-oral step-down therapy in which patients are started on the intravenous formulation of eravacycline and then stepped down to an oral formulation of eravacycline could reduce the length of a patient�� hospital stay or help avoid hospital admission altogether, lowering the overall cost of care for these patients.

Advisors' Opinion:

• [By Roberto Pedone]

  Another under-$10 biopharmaceutical player that's starting to trend within range of triggering a near-term breakout trade is Tetraphase Pharmaceuticals (TTPH), which using its proprietary chemistry technology creates novel antibiotics for serious and life-threatening multi-drug resistant infections. This stock is off to a strong start in 2013, with shares up 19.4%.

  If you take a look at the chart for Tetraphase Pharmaceuticals, you'll notice that this stock has just started to trend back above its 50-day moving average of $7.76 a share with decent upside volume flows. That move is quickly pushing shares of TTPH within range of breaking out above some key near-term overhead resistance levels that have acted as a ceiling for the stock for the last three months.

  Market players should now look for long-biased trades in TTPH if it manages to break out above some near-term overhead resistance levels at $8.30 to $8.40 a share and then once it takes out more resistance at $8.50 to $9 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 62,234 shares. If that breakout triggers soon, then TTPH will set up to re-test or possibly take out its all-time high at $9.66 a share. Any high-volume move above that level will then push TTPH into new all-time high territory, which is bullish technical price action. Some possible upside targets off that move are $12 to $13 a share.

  Traders can look to buy TTPH off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $7.76 a share, or below more key near-term support levels at $7.37 to $7.02 a share. One can also buy TTPH off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.